ITEM 7.01 REGULATION FD DISCLOSURE
On January 12, 2020, Zymeworks Inc. issued a press release announcing the
initiation of a Phase 2 trial evaluating ZW25 combination therapy and an
agreement with Pfizer which advances the study. On January 13, 2020, this press
release was filed with the Canadian securities regulatory authorities in Canada
on the System for Electronic Document Analysis and Retrieval ("SEDAR") at
www.sedar.com. A copy of this press release is attached as exhibit 99.1 hereto.
On January 13, 2020, Zymeworks Inc. issued a press release highlighting its key
accomplishments in 2019, providing updated corporate priorities, and announcing
multiple clinical program advances for its lead candidates, ZW25 and ZW49. On
January 13, 2020, this press release was filed with the Canadian securities
regulatory authorities in Canada on SEDAR at www.sedar.com. A copy of this press
release is attached as exhibit 99.2 hereto.
The information provided under this Item (including exhibits 99.1 and 99.2,
attached hereto) shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
Exhibit No. Description
99.1 Press Release dated January 12, 2020.
99.2 Press Release dated January 13, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses